Brief: Instil Bio Announces Resumption Of Clinical Trial Of CoStAR-TIL Candidate ITIL-306

Instil Bio

09/01/2023 12:42

Jan 9 (Reuters) - Instil Bio Inc  TIL.O :
    * INSTIL BIO ANNOUNCES RESUMPTION OF CLINICAL TRIAL OF
COSTAR-TIL
CANDIDATE ITIL-306 IN LUNG, OVARIAN, AND RENAL CANCER
    * INSTIL BIO ANNOUNCES RESUMPTION OF CLINICAL TRIAL OF
COSTAR-TIL
CANDIDATE ITIL-306 IN LUNG, OVARIAN, AND RENAL CANCER
    * INSTIL BIO INC - PHASE 1 TRIAL OF ITIL-306 IN NSCLC,
OVARIAN,
AND RCC RE-OPENED TO ENROLLMENT AFTER VOLUNTARY PAUSE
    * INSTIL BIO INC - INITIAL DATA READOUT FOR ITIL-306
EXPECTED IN
2023
    * INSTIL BIO INC - WITH RECENT REPRIORITIZATION OF CLINICAL
PROGRAMS AND CORPORATE RESTRUCTURING, COMPANY EXPECTS CASH
RUNWAY INTO 2025

Source text for Eikon:  ID:nGNX3Vw1xq 
Further company coverage:  TIL.O 
 ((Reuters.Briefs@thomsonreuters.com;))